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lower respiratory tract infections at the Hajj are caused
by pneumococci.4
To determine the coverage of PPV among British pil-
grims, we surveyed 195 UK travelers (aged 1 to 83 years)
who attended our temporary clinics in Mecca during the
Hajj 2005. The majority were men (91%) and of subcon-
tinental ethnicities (84%). Fifty three (27%) were in an
at-risk disease category (25 diabetic, 10 cardiac, and 10
pulmonary patients) and 8were older than 65 years. Only
10 of 195 British pilgrims (5%) reported PPV immuniza-
tion. Eight of them were at-risk individuals (5 diabetic, 1
cardiac, 2 elderly patients), equating to a vaccine uptake
rate of 15% in at-risk Hajj pilgrims. Among the 195 pil-
grims, 30 (15%) were smokers, of whom 7 were at-risk
individuals and only 1 was immunized. None of those re-
porting chronic lung diseases had received the vaccine.
The low uptake of PPV among at-risk adults in our
survey, as in other studies, is worrying given the vac-
cine’s benefit in reducing intensive care unit admis-
sions.1-3 An estimated 55 000 pilgrims from Europe and
North America were expected to attend the Hajj pilgrim-
age by mid December 2007. At least one-fourth of these
pilgrims would be eligible for PPV, but it can be extrapo-
lated from the current studies that 85% to 90% of at-risk
pilgrims will miss out.1,2 A sustained effort is needed to
improve the uptake of the vaccine among the Hajj pil-
grims. There is still time to act in relation to this year’s
Hajj, and we urge physicians and other health care pro-
fessionals advising Hajj pilgrims to ensure that those at
risk are offered pneumococcal vaccine.
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Risks of Combining Immunosuppressive
and Biological Treatments
in Inflammatory Bowel Disease
S orrentino et al
1 report the results of infliximabwith
low-dosemethotrexate for the prevention of post-
surgical recurrence of ileocolonic Crohn disease
(CD). The authors elected to coadminister methotrex-
ate because it is known to reduce the long-term immu-
nogenicity of infliximab.2 This is true only with epi-
sodic treatment with infliximab. Despite the observation
that therapywith concomitant immunosuppressive agents
reduces the development of antibodies against biologi-
cal treatments, the authors have not significantly al-
tered the response to infliximab3 in the treatment of CD
when the agents are administered as an induction course
followed by scheduled maintenance treatment. Re-
cently, Maser et al4 demonstrated that the rate of clini-
cal remission was higher for patients with a detectable
trough serum concentration of infliximab comparedwith
patients in whom serum infliximabwas undetectable, in-
cluding those without antibodies (82% vs 6%; P .001).
In this study, concurrent immunomodulators did not al-
ter outcomes.4 A preliminary report from Van Assche et
al5 suggested that the immunosuppressive therapy could
be discontinued after 6months with no effect on the loss
of response to infliximab over 2 years. So the concept of
combination immunosuppressive therapy needs to be dis-
cussed in light of the expanding reports of potential in-
creases in severe infections and neoplasms.6
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In reply
We thank Roblin and Phelip for their comment on a timely
issue. The recent report of the rare hepatosplenic T-cell lym-
phoma (HSTCL) in young patients with CD treated with
both infliximab and azathioprine or steroids1 has rightly un-
leashed a series of doubts regarding the optimal use of bio-
logical agents in this and other conditions.2 How these ob-
servationsmay directly relate to the design of our study3—as
implied by Roblin and Phelip—is unclear though.While aza-
thioprine by itself has been linked to lymphoma develop-
ment including HSTCL,1 recent studies have shown that nei-
ther infliximab nor methotrexate, which was used in our
study, alone or in combination in CD4 or in rheumatoid ar-
thritis,5 appear to be associated with an increased risk of
developing lymphomas. In addition, methotrexate alone has
never been associated thus far with HSTCL in CD.1
The report by Mackey et al1 on HSTCL is undoubtedly
disturbing and should be taken into due consideration. Nev-
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ertheless, we should keep inmind that biological agents have
been largely used so far in patients with advanced, severe
disease, be it rheumatoid arthritis or CD. These patientsmay
be irreversibly bound to develop long-standing complica-
tions—including lymphoma and other cancers—driven by
inflammation or an intrinsic immune defect regardless of
concomitant therapy,6 therapywhich is often sentenced guilty
by association. Unfortunately, especially in CD, real mea-
sures of disease heterogeneity and progression (such as du-
ration of inflammation before symptom onset) are still lack-
ing, making proper stratification extremely difficult.
A question to be asked is whether the combination of in-
fliximab and immunosuppressives (andmore specificallyme-
tothrexate) in CD is superior to monotherapy with inflixi-
mab alone. Available data indicate that the benefit may be
limited to reduction of infusion reactions and increase in se-
rum infliximab levels.2 Whether the latter effects, directly or
indirectly, translate intogreater efficacy isunclear.Whilemany
advocate the use of immunosuppressives only in episodic in-
fliximab treatment,2 others suggest thatmethotrexatemaybring
a benefit even in maintenance infliximab treatment.7
Because there is no established role for methotrexate in
prevention of postsurgical recurrence in CD, we do not know
whethermethotrexate affected the outcome of our study. Pre-
liminary observations suggest that patients who switched
to monotherapy with infliximab may do as well as the oth-
ers (D.S., unpublished data, 2008). A definite answer may
only come from a future randomized controlled trial we are
planning to conduct that will not include methotrexate and
that will target for therapy only patients at high risk of de-
veloping recurrence. In the meantime, we believe that our
study may open up a new venue for the management of CD.
The future challenge is to use this information properly by
finding ways to optimize efficacy and the overall risk-
benefit ratio.
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